Vesicular monoamine transporter 2: Role as a novel target for drug development

A psychomotor stimulant theory of addiction.

Wise, R. A., & Bozarth, M. A. (1987) · Psychological Review · doi:10.1037/0033-295x.94.4.469 · Cited by 2,747 · see citing works

[3H]Ketanserin (R 41 468), a selective 3H-ligand for serotonin2 receptor binding sites. Binding properties, brain distribution, and functional role.

Leysen, J. E., Niemegeers, C. J. E., Nueten, J. M. V., & Laduron, P. M. (1982) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)14623-3 · Cited by 1,071 · see citing works

Drug Facts and Comparisons 1991.

(1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-114-9-823_1 · Cited by 776 · see citing works

Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse transport

Sulzer, D., Chen, T., Lau, Y., Kristensen, H., Rayport, S., & Ewing, A. (1995) · The Journal of Neuroscience · doi:10.1523/jneurosci.15-05-04102.1995 · Cited by 688 · see citing works

Neural Mechanisms of Drug Reinforcementa

Koob, G. F. (1992) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1992.tb25966.x · Cited by 607 · see citing works

A cDNA that suppresses MPP+ toxicity encodes a vesicular amine transporter

Liu, Y. (1992) · Cell · doi:10.1016/0092-8674(92)90425-c · Cited by 589 · see citing works

Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental lewy body disease

Jenner, P. G., Dexter, D. T., Sian, J., Schapira, A. H. V., & MARSDEN, C. D. (1992) · Annals of Neurology · doi:10.1002/ana.410320714 · Cited by 545 · see citing works

Expression cloning of a reserpine-sensitive vesicular monoamine transporter.

Erickson, J. D., Eiden, L. E., & Hoffman, B. J. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.22.10993 · Cited by 488 · see citing works

Distinct pharmacological properties and distribution in neurons and endocrine cells of two isoforms of the human vesicular monoamine transporter.

Erickson, J. D., Schäfer, M., Bonner, T. I., Eiden, L. E., & Weihe, E. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.10.5166 · Cited by 480 · see citing works

Tetrabenazine as antichorea therapy in Huntington disease: A randomized controlled trial

Huntington Study Group (2006) · Neurology · doi:10.1212/01.wnl.0000198586.85250.13 · Cited by 471 · see citing works

VMAT2 knockout mice: Heterozygotes display reduced amphetamine-conditioned reward, enhanced amphetamine locomotion, and enhanced MPTP toxicity

Takahashi, N., Miner, L. L., Sora, I., Ujike, H., Revay, R. S., Kostić, V., Jackson-Lewis, V. R., Przedborski, S., & Uhl, G. R. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.18.9938 · Cited by 429 · see citing works

Amphetamine and other psychostimulants reduce pH gradients in midbrain dopaminergic neurons and chromaffin granules: a mechanism of action

Sulzer, D., & Rayport, S. (1990) · Neuron · doi:10.1016/0896-6273(90)90339-h · Cited by 389 · see citing works

Knockout of the Vesicular Monoamine Transporter 2 Gene Results in Neonatal Death and Supersensitivity to Cocaine and Amphetamine

Wang, Y.-M., Gainetdinov, R. R., Fumagalli, F., Xu, F., Jones, S. R., Bock, C. B., Miller, G. W., Wightman, R. M., & Caron, M. G. (1997) · Neuron · doi:10.1016/s0896-6273(00)80419-5 · Cited by 376 · see citing works

Long-term effects of tetrabenazine in hyperkinetic movement disorders

Jankovic, J. J., & Beach, J. (1997) · Neurology · doi:10.1212/wnl.48.2.358 · Cited by 355 · see citing works

Differential expression of two vesicular monoamine transporters

Peter, D., Liu, Y., Sternini, C., GIORGIO, R. D., Brecha, N. C., & Edwards, R. (1995) · Journal of Neuroscience · doi:10.1523/jneurosci.15-09-06179.1995 · Cited by 333 · see citing works

Accumulation of biological amines into chromaffin granules: a model for hormone and neurotransmitter transport

Johnson, R. G. (1988) · Physiological Reviews · doi:10.1152/physrev.1988.68.1.232 · Cited by 323 · see citing works

Tetrabenazine as antichorea therapy in Huntington disease: A randomized controlled trial

Savani, A. A., & Login, I. S. (2007) · Neurology · doi:10.1212/01.wnl.0000259143.52138.5c · Cited by 298 · see citing works

MPTP

Snyder, S. H., & D’Amato, R. J. (1986) · Neurology · doi:10.1212/wnl.36.2.250 · Cited by 295 · see citing works

THE ROLE OF VESICULAR TRANSPORT PROTEINS IN SYNAPTIC TRANSMISSION AND NEURAL DEGENERATION

Liu, Y., & Edwards, R. H. (1997) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.20.1.125 · Cited by 295 · see citing works

Amphetamine and Other Weak Bases Act to Promote Reverse Transport of Dopamine in Ventral Midbrain Neurons

Sulzer, D. L., Maidment, N. T., & Rayport, S. (1993) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1993.tb03181.x · Cited by 292 · see citing works

Neurotransmitter transporters as molecular targets for addictive drugs

Amara, S. G., & Sonders, M. S. (1998) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(98)00068-4 · Cited by 288 · see citing works

New insights into the cause of Parkinson's disease

Jenner, P., Schapira, A. H. V., & MARSDEN, C. D. (1992) · Neurology · doi:10.1212/wnl.42.12.2241 · Cited by 272 · see citing works

Increased Methamphetamine Neurotoxicity in Heterozygous Vesicular Monoamine Transporter 2 Knock-Out Mice

Fumagalli, F., Gainetdinov, R. R., Wang, Y., Valenzano, K. J., Miller, G. W., & Caron, M. G. (1999) · Journal of Neuroscience · doi:10.1523/jneurosci.19-07-02424.1999 · Cited by 241 · see citing works

Localization of vesicular monoamine transporter isoforms (VMAT1 and VMAT2) to endocrine cells and neurons in rat

Weihe, E., Schäfer, M. K.-H., Erickson, J. D., & Eiden, L. E. (1994) · Journal of Molecular Neuroscience · doi:10.1007/bf02736730 · Cited by 230 · see citing works

The chromaffin granule and synaptic vesicle amine transporters differ in substrate recognition and sensitivity to inhibitors.

Peter, D., Jimenez, J., Liu, Y., Kim, M., & Edwards, R. H. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)37272-1 · Cited by 227 · see citing works

A novel mechanism of action and potential use for lobeline as a treatment for psychostimulant abuse

Dwoskin, L. P., & Crooks, P. A. (2002) · Biochemical Pharmacology · doi:10.1016/s0006-2952(01)00899-1 · Cited by 219 · see citing works

Nicotinic receptor agonists exhibit anxiolytic-like effects on the elevated plus-maze test

Brioni, J. D., O'Neill, A. B., Kim, D. J. B., & Decker, M. W. (1993) · European Journal of Pharmacology · doi:10.1016/0014-2999(93)90498-7 · Cited by 216 · see citing works

The etiology of Parkinson's disease with emphasis on the MPTP story

Langston, J. W. (1996) · Neurology · doi:10.1212/wnl.47.6_suppl_3.153s · Cited by 180 · see citing works

Increased MPTP Neurotoxicity in Vesicular Monoamine Transporter 2 Heterozygote Knockout Mice

Gainetdinov, R. R., Fumagalli, F., Wang, Y., Jones, S. R., Levey, A. I., Miller, G. W., & Caron, M. G. (1998) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1998.70051973.x · Cited by 178 · see citing works

Benzoquinolizine Derivatives: a New Class of Monamine Decreasing Drugs With Psychotropic Action

Pletscher, A., BROSSI, A., & GEY, K. F. (1962) · International review of neurobiology · doi:10.1016/s0074-7742(08)60024-0 · Cited by 168 · see citing works

Radioligands of the vesicular monoamine transporter and their use as markers of monoamine storage vesicles

Henry, J., & Scherman, D. (1989) · Biochemical Pharmacology · doi:10.1016/0006-2952(89)90082-8 · Cited by 165 · see citing works

Methamphetamine Rapidly Decreases Vesicular Dopamine Uptake

Brown, J. M., Hanson, G. R., & Fleckenstein, A. E. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0742221.x · Cited by 158 · see citing works

Tetrabenazine in the treatment of hyperkinetic movement disorders

Kenney, C., & Jankovic, J. J. (2006) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.6.1.7 · Cited by 158 · see citing works

Functional Identification and Molecular Cloning of a Human Brain Vesicle Monoamine Transporter

Erickson, J. D., & Eiden, L. E. (1993) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1993.tb07476.x · Cited by 158 · see citing works

Parkinsons Disease - Redox Mechanisms

Adams, J. D., Jr., Chang, M., & Klaidman, L. K. (2001) · Current Medicinal Chemistry · doi:10.2174/0929867013372995 · Cited by 139 · see citing works

Reserpine binding to bovine chromaffin granule membranes. Characterization and comparison with dihydrotetrabenazine binding.

Scherman, D., & Henry, J. (1984) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)15021-9 · Cited by 136 · see citing works

Regulation of the Vesicular Monoamine Transporter-2: A Novel Mechanism for Cocaine and Other Psychostimulants

Brown, J. M., Hanson, G. R., & Fleckenstein, A. E. (2001) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38814-7 · Cited by 135 · see citing works

Lobeline and Nicotine Evoke [3H]Overflow from Rat Striatal Slices Preloaded with [3H]Dopamine: Differential Inhibition of Synaptosomal and Vesicular [3H]Dopamine Uptake

Teng, L., Crooks, P. A., Sonsalla, P. K., & Dwoskin, L. P. (1997) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36537-1 · Cited by 133 · see citing works

Neuroprotective effects of the dopamine D 2 /D 3 agonist pramipexole against postischemic or methamphetamine-induced degeneration of nigrostriatal neurons

Hall, E. D., Andrus, P. K., Oostveen, J. A., Althaus, J. S., & Voigtlander, P. F. V. (1996) · Brain Research · doi:10.1016/s0006-8993(96)00968-7 · Cited by 133 · see citing works

Tetrabenazine in the treatment of hyperkinetic movement disorders.

Jankovic, J. J. (1983) · PubMed · Cited by 129 · see citing works

Characterization of the monoamine carrier of chromaffin granule membrane by binding of [2-3H]dihydrotetrabenazine.

Scherman, D., Jaudon, P., & Henry, J. (1983) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.80.2.584 · Cited by 126 · see citing works

The binding of L-[3H]nicotine to a single class of high affinity sites in rat brain membranes.

Lippiello, P. M., & Fernandes, K. G. (1986) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)10280-0 · Cited by 123 · see citing works

Mice with Very Low Expression of the Vesicular Monoamine Transporter 2 Gene Survive into Adulthood: Potential Mouse Model for Parkinsonism

Mooslehner, K. A., Chan, P. M., Xu, W., Liu, L., Smadja, C., Humby, T., Allen, N. D., Wilkinson, L. S., & Emson, P. C. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.16.5321-5331.2001 · Cited by 118 · see citing works

Role of monoamine transporters in mediating psychostimulant effects

Riddle, E. L., Fleckenstein, A. E., & Hanson, G. R. (2005) · The AAPS Journal · doi:10.1208/aapsj070481 · Cited by 117 · see citing works

Dissociations between the locomotor stimulant and depressant effects of nicotinic agonists in rats

Stolerman, I. P., Garcha, H. S., & Mirza, N. R. (1995) · Psychopharmacology · doi:10.1007/bf02246215 · Cited by 113 · see citing works

Monoamine Oxidase and Mitochondrial Respiration

Cohen, G., & Kesler, N. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.0732310.x · Cited by 113 · see citing works

Further studies on nicotine-induced conditioned place preference in the rat

Fudala, P. J., & Iwamoto, E. T. (1986) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(86)90083-3 · Cited by 112 · see citing works

Lobeline Attenuates d-Methamphetamine Self-Administration in Rats

Harrod, S. B., Dwoskin, L. P., Crooks, P. A., Klebaur, J. E., & Bardo, M. T. (2001) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29365-4 · Cited by 111 · see citing works

Activation and inhibition of the human α7 nicotinic acetylcholine receptor by agonists

Briggs, C. A., & McKenna, D. G. (1998) · Neuropharmacology · doi:10.1016/s0028-3908(98)00110-5 · Cited by 108 · see citing works

Gain-of-function haplotypes in the vesicular monoamine transporter promoter are protective for Parkinson disease in women

Glatt, C. E., Wahner, A. D., White, D. J., Ruiz‐Linares, A., & Ritz, B. R. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi445 · Cited by 108 · see citing works

Lobeline Displaces [3H]Dihydrotetrabenazine Binding and Releases [3H]Dopamine from Rat Striatal Synaptic Vesicles: Comparison with d‐Amphetamine

Teng, L., Crooks, P. A., & Dwoskin, L. P. (1998) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1998.71010258.x · Cited by 108 · see citing works

Effects of lobeline, a nicotinic receptor agonist, on learning and memory

Decker, M. W., Majchrzak, M. J., & Arnerić, S. P. (1993) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(93)90508-q · Cited by 107 · see citing works

Methylphenidate Alters Vesicular Monoamine Transport and Prevents Methamphetamine-Induced Dopaminergic Deficits

Sandoval, V., Riddle, E. L., Hanson, G. R., & Fleckenstein, A. E. (2003) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.045005 · Cited by 104 · see citing works

[3H]methoxytetrabenazine: A high specific activity ligand for estimating monoaminergic neuronal integrity

Borght, T. M. V., Sima, A. A. F., Kilbourn, M. R., Desmond, T. J., Kuhl, D. E., & Frey, K. A. (1995) · Neuroscience · doi:10.1016/0306-4522(95)00167-h · Cited by 99 · see citing works

Inhibition of Brain Vesicular Monoamine Transporter (VMAT2) Enhances 1-Methyl-4-phenylpyridinium Neurotoxicity In Vivo in Rat Striata

Staal, R. G. W., & Sonsalla, P. K. (2000) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)39240-7 · Cited by 98 · see citing works

Binding of α-dihydrotetrabenazine to the vesicular monoamine transporter is stereospecific

Kilbourn, M. R., Lee, L., Borght, T. V., Jewett, D. M., & Frey, K. A. (1995) · European Journal of Pharmacology · doi:10.1016/0014-2999(95)00162-e · Cited by 98 · see citing works

Pharmacology of Lobeline, A Nicotinic Receptor Ligand

Damaj, M. I., Patrick, G., Creasy, K. R., & Martin, B. R. (1997) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36807-7 · Cited by 96 · see citing works

Relations between structure and nicotine‐like activity: X‐ray crystal structure analysis of (−)−cytisine and (−)−lobeline hydrochloride and a comparison with (−)−nicotine and other nicotine‐like compounds

Barlow, R. B., & Johnson, O. W. (1989) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1989.tb14608.x · Cited by 94 · see citing works

Impact of psychostimulants on vesicular monoamine transporter function

Fleckenstein, A. E., & Hanson, G. R. (2003) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2003.08.077 · Cited by 93 · see citing works

Equilibrium versus Compartmental Analysis for Assessment of the Vesicular Monoamine Transporter Using (+)-α-[ 11 C]Dihydrotetrabenazine (DTBZ) and Positron Emission Tomography

Koeppe, R. A., Frey, K. A., Kume, A., Albin, R. L., Kilbourn, M. R., & Kuhl, D. E. (1997) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-199709000-00001 · Cited by 90 · see citing works

Charged Residues in Transmembrane Domains II and XI of a Vesicular Monoamine Transporter Form a Charge Pair That Promotes High Affinity Substrate Recognition

Merickel, A., Kaback, H. R., & Edwards, R. H. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.9.5403 · Cited by 88 · see citing works

Energy-driven uptake of the neurotoxin 1-methyl-4-phenylpyridinium into chromaffin granules via the catecholamine transporter.

Daniels, A. J., & Reinhard, J. F. (1988) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)60674-x · Cited by 87 · see citing works

Lobeline Inhibits the Neurochemical and Behavioral Effects of Amphetamine

Miller, D. K., Crooks, P. A., Teng, L., Witkin, J. M., Munzar, P., Goldberg, S. R., Acri, J. B., & Dwoskin, L. P. (2001) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38847-0 · Cited by 86 · see citing works

Ketanserin binds to the monoamine transporter of chromaffin granules and of synaptic vesicles.

Darchen, F., Scherman, D., Laduron, P. M., & Henry, J. (1988) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)13392-0 · Cited by 86 · see citing works

Reserpine binding to chromaffin granules suggests the existence of two conformations of the monoamine transporter

Darchen, F., Scherman, D., & Henry, J. P. (1989) · Biochemistry · doi:10.1021/bi00430a040 · Cited by 85 · see citing works

[3H]Dihydrotetrabenazine, a New In Vitro Monoaminergic Probe for Human Brain

Scherman, D., Raisman‐Vozari, R., Ploska, A., & Agid, Y. (1988) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1988.tb10583.x · Cited by 85 · see citing works

Identification of Residues Involved in Substrate Recognition by a Vesicular Monoamine Transporter

Merickel, A., Rosandich, P., Peter, D., & Edwards, R. H. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.43.25798 · Cited by 81 · see citing works

A simple synthesis of [11C]Dihydrotetrabenazine (DTBZ)

Jewett, D. M., Kilbourn, M. R., & Lee, L. C. (1997) · Nuclear Medicine and Biology · doi:10.1016/s0969-8051(96)00213-2 · Cited by 79 · see citing works

Tetrabenazine, an amine-depleting drug, also blocks dopamine receptors in rat brain.

Reches, A., Burke, R. E., Kuhn, C. M., Hassan, M. N., Jackson, V., & Fahn, S. (1983) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)33621-9 · Cited by 75 · see citing works

Reinforcing Effects of Nicotinic Compounds Intravenous Self-administration in Drug-Naive Mice

Rasmussen, T. (1998) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(98)00003-3 · Cited by 73 · see citing works

Lobeline Analogs with Enhanced Affinity and Selectivity for Plasmalemma and Vesicular Monoamine Transporters

Miller, D. K., Crooks, P. A., Zheng, G., Grinevich, V. P., Norrholm, S. D., & Dwoskin, L. P. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.068098 · Cited by 73 · see citing works

Lobeline inhibits nicotine-evoked [3H]dopamine overflow from rat striatal slices and nicotine-evoked 86Rb+ efflux from thalamic synaptosomes

Miller, D. K., Crooks, P. A., & Dwoskin, L. P. (2000) · Neuropharmacology · doi:10.1016/s0028-3908(00)00140-4 · Cited by 70 · see citing works

Selective MPP+ uptake into synaptic dopamine vesicles: possible involvement in MPTP neurotoxicity

Zompo, M. D., Piccardi, M. P., Ruiu, S., Quartu, M., GESSA, G. L., & Vaccari, A. (1993) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1993.tb13584.x · Cited by 69 · see citing works

Syntheseversuche in der Emetin‐Reihe. 1. Mitteilung. 2‐Oxo‐hydrobenzo[a]chinolizine

BROSSI, A., Lindlar, H., Walter, M. G., & Schnider, O. (1958) · Helvetica Chimica Acta · doi:10.1002/hlca.660410117 · Cited by 68 · see citing works

In Vivo Imaging of Vesicular Monoamine Transporters in Human Brain Using [11C]Tetrabenazine and Positron Emission Tomography

Kilbourn, M. R., DaSilva, J. N., Frey, K. A., Koeppe, R. A., & Kuhl, D. E. (1993) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1993.tb03521.x · Cited by 68 · see citing works

Differential stereoselective pharmacokinetics of pantoprazole, a proton pump inhibitor in extensive and poor metabolizers of pantoprazole?a preliminary study

Tanaka, M., Yamazaki, H., Hakusui, H., Nakamichi, N., & Sekino, H. (1997) · Chirality · doi:10.1002/(sici)1520-636x(1997)9:1 · Cited by 67 · see citing works

Brain nicotinic acetylcholine receptors. Biochemical characterization by neosurugatoxin.

Yamada, S., Isogai, M., Kagawa, Y., Takayanagi, N., Hayashi, E. Y., Tsuji, K., & Kosuge, T. (1985) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)13496-2 · Cited by 65 · see citing works

The comparative binding characteristics of nicotinic ligands and their pharmacology

Sloan, J. W., Martin, W. R., Bostwick, M., Hook, R. H., & Wala, E. P. (1988) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(88)90454-6 · Cited by 64 · see citing works

Defunctionalized Lobeline Analogues: Structure−Activity of Novel Ligands for the Vesicular Monoamine Transporter

Zheng, G., Dwoskin, L. P., Deaciuc, A. G., Norrholm, S. D., & Crooks, P. A. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm0501228 · Cited by 63 · see citing works

Identification of nonserotonergic [3H]ketanserin binding sites associated with nerve terminals in rat brain and with platelets; relation with release of biogenic amine metabolites induced by ketanserin- and tetrabenazine-like drugs.

Leysen, J. E., Eens, A., Gommeren, W., Gompel, P. V., Wynants, J., & Janssen, P. A. J. (1988) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)24276-8 · Cited by 63 · see citing works

Neuroprotective effects of the dopamine agonists pramipexole and bromocriptine in 3-acetylpyridine-treated rats

Sethy, V. H., Wu, H., Oostveen, J. A., & Hall, E. D. (1997) · Brain Research · doi:10.1016/s0006-8993(97)00075-9 · Cited by 61 · see citing works

The neurotoxin 1-methyl-4-phenylpyridinium is sequestered within neurons that contain the vesicular monoamine transporter

Speciale, S. G., Liang, C., Sonsalla, P. K., Edwards, R. H., & German, D. C. (1998) · Neuroscience · doi:10.1016/s0306-4522(97)00570-8 · Cited by 59 · see citing works

In vivo imaging of the brain vesicular monoamine transporter.

Borght, T. M. V., Kilbourn, M. R., Koeppe, R. A., DaSilva, J. N., Carey, J. E., Kuhl, D. E., & Frey, K. A. (1995) · PubMed · Cited by 57 · see citing works

Metabolic studies of tetrabenazine, a psychotropic drug in animals and man

Schwartz, D. E., Bruderer, H., Rieder, J., & BROSSI, A. (1966) · Biochemical Pharmacology · doi:10.1016/0006-2952(66)90031-1 · Cited by 56 · see citing works

Lobeline attenuates locomotor stimulation induced by repeated nicotine administration in rats

Miller, D. K., Harrod, S. B., Green, T. A., Wong, M.-Y., Bardo, M. T., & Dwoskin, L. P. (2002) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(02)00996-6 · Cited by 54 · see citing works

Lobeline does not serve as a reinforcer in rats

Harrod, S. B., Dwoskin, L. P., Green, T. A., Gehrke, B. J., & Bardo, M. T. (2003) · Psychopharmacology · doi:10.1007/s00213-002-1289-6 · Cited by 51 · see citing works

Nicotine‐Stimulated Release of [³H]Norepinephrine from Fetal Rat Locus Coeruleus Cells in Culture

Gallardo, K. A., & Leslie, F. M. (1998) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1998.70020663.x · Cited by 51 · see citing works

In vivo specific binding of [3H]-1-nicotine in the mouse brain

Broussolle, E. P., Wong, D. F., Fanelli, R. J., & London, E. D. (1989) · Life Sciences · doi:10.1016/0024-3205(89)90340-8 · Cited by 47 · see citing works

Chimeric Vesicular Monoamine Transporters Identify Structural Domains That Influence Substrate Affinity and Sensitivity to Tetrabenazine

Peter, D., Vu, T., & Edwards, R. H. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.6.2979 · Cited by 47 · see citing works

EFFECT OF NEUROLEPTICS AND OTHER DRUGS ON MONOAMINE UPTAKE BY MEMBRANES OF ADRENAL CHROMAFFIN GRANULES

Pletscher, A. (1977) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1977.tb08395.x · Cited by 47 · see citing works

[3H]Dihydrotetrabenazine, a new marker for the visualization of dopaminergic denervation in the rat striatum

Masuo, Y., Pélaprat, D., Scherman, D., & Rostène, W. H. (1990) · Neuroscience Letters · doi:10.1016/0304-3940(90)90426-a · Cited by 46 · see citing works

Individual Residues Contribute to Multiple Differences in Ligand Recognition between Vesicular Monoamine Transporters 1 and 2

Finn, J. P., & Edwards, R. H. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.26.16301 · Cited by 43 · see citing works

Pharmacological inactivation of the vesicular monoamine transporter can enhance 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurodegeneration of midbrain dopaminergic neurons, but not locus coeruleus noradrenergic neurons

German, D. C., Liang, C., Manaye, K. F., Lane, K. B., & Sonsalla, P. K. (2000) · Neuroscience · doi:10.1016/s0306-4522(00)00385-7 · Cited by 41 · see citing works

Ontogeny of vesicular monoamine transporter mRNAs VMAT1 and VMAT2

Hansson, S. R., Mezey, É., & Hoffman, B. J. (1998) · Developmental Brain Research · doi:10.1016/s0165-3806(98)00103-5 · Cited by 40 · see citing works

Pramipexole increases vesicular dopamine uptake: implications for treatment of Parkinson's neurodegeneration

Truong, J. G., Rau, K. S., Hanson, G. R., & Fleckenstein, A. E. (2003) · European Journal of Pharmacology · doi:10.1016/s0014-2999(03)02080-6 · Cited by 39 · see citing works

Lobelane analogues as novel ligands for the vesicular monoamine transporter-2

Zheng, G., Dwoskin, L. P., Deaciuc, A. G., Zhu, J., Jones, M. D., & Crooks, P. A. (2005) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2005.04.013 · Cited by 38 · see citing works

In vivo imaging of monoaminergic nerve terminals in normal and MPTP‐lesioned primate brain using positron emission tomography (PET) and [11C]tetrabenazine

DaSilva, J. N., Kilbourn, M. R., & Domino, E. F. (1993) · Synapse · doi:10.1002/syn.890140205 · Cited by 38 · see citing works

Mutagenesis and Derivatization of Human Vesicle Monoamine Transporter 2 (VMAT2) Cysteines Identifies Transporter Domains Involved in Tetrabenazine Binding and Substrate Transport

Thiriot, D. S., & Ruoho, A. E. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m103947200 · Cited by 37 · see citing works

Characterization of [11C]tetrabenazine as an in vivo radioligand for the vesicular monoamine transporter

DaSilva, J. N., Carey, J. E., Sherman, P. S., Pisani, T., & Kilbourn, M. R. (1994) · Nuclear Medicine and Biology · doi:10.1016/0969-8051(94)90003-5 · Cited by 37 · see citing works

Characteristics of the transport of the quaternary ammonium 1-methyl-4-phenylpyridinium by chromaffin granules

Darchen, F., Scherman, D., Desnos, C., & Henry, J. (1988) · Biochemical Pharmacology · doi:10.1016/0006-2952(88)90621-1 · Cited by 33 · see citing works

Uptake of the Neurotoxin, 4-MethylphenylPyridinium, into Chromaffin Granules and Synaptic Vesicles: A Proton Gradient Drives Its Uptake through Monoamine Transporter

Moriyama, Y., Amakatsu, K., & Futai, M. (1993) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1993.1422 · Cited by 32 · see citing works

Peptide Mapping of the [125I]Iodoazidoketanserin and [125I]2-N-[(3′-Iodo-4′-azidophenyl)propionyl]tetrabenazine Binding Sites for the Synaptic Vesicle Monoamine Transporter

Sievert, M. K., & Ruoho, A. E. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.41.26049 · Cited by 32 · see citing works

Characterization of high-affinity [3H]TBZOH binding to the human platelet vesicular monoamine transporter

Zucker, M., Weizman, A., & Rehavi, M. (2001) · Life Sciences · doi:10.1016/s0024-3205(01)01301-7 · Cited by 31 · see citing works

Psychostimulants and Vesicle Trafficking: A Novel Mechanism and Therapeutic Implications

Hanson, G. R., Sandoval, V., Riddle, E. L., & Fleckenstein, A. E. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1316.019 · Cited by 31 · see citing works

Photoaffinity labeling of the monoamine transporter of bovine chromaffin granules and other monamine storage vesicles using 7-azide-8-[125I]iodoketanserin

Isambert, M. F., Gasnier, B., Laduron, P. M., & Henry, J. P. (1989) · Biochemistry · doi:10.1021/bi00431a044 · Cited by 31 · see citing works

Tetrabenazine-induced depletion of brain monoamines: Mechanism by which desmethylimipramine protects cortical norepinephrine

Pettibone, D. J., Pflueger, A. B., & Totaro, J. A. (1984) · European Journal of Pharmacology · doi:10.1016/0014-2999(84)90563-6 · Cited by 30 · see citing works

Synthesis of a [11C]Methoxy derivative of α-Dihydrotetrabenazine: a radioligand for studying the vesicular monoamine transporter

DaSilva, J. N., Kilbourn, M. R., & Mangner, T. J. (1993) · Applied Radiation and Isotopes · doi:10.1016/0969-8043(93)90103-h · Cited by 30 · see citing works

Hydrophobicity of the tetrabenazine-binding site of the chromaffin granule monoamine transporter.

Scherman, D., Gasnier, B., Jaudon, P., & Henry, J. (1988) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)13112-x · Cited by 30 · see citing works

Synthesis of [11C]tetrabenazine, a vesicular monoamine uptake inhibitor, for PET imaging studies

DaSilva, J. N., Kilbourn, M. R., & Mangner, T. J. (1993) · Applied Radiation and Isotopes · doi:10.1016/0969-8043(93)90130-3 · Cited by 29 · see citing works

Apomorphine increases vesicular monoamine transporter-2 function: implications for neurodegeneration

Truong, J. G., Hanson, G. R., & Fleckenstein, A. E. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2004.03.060 · Cited by 29 · see citing works

Identification of Human Vesicle Monoamine Transporter (VMAT2) Lumenal Cysteines That Form an Intramolecular Disulfide Bond

Thiriot, D. S., Sievert, M. K., & Ruoho, A. E. (2002) · Biochemistry · doi:10.1021/bi015779j · Cited by 28 · see citing works

In Vitro and in Vivo Studies of Benzisoquinoline Ligands for the Brain Synaptic Vesicle Monoamine Transporter

Lee, L. C., Borght, T. V., Sherman, P. S., Frey, K. A., & Kilbourn, M. R. (1996) · Journal of Medicinal Chemistry · doi:10.1021/jm950117b · Cited by 27 · see citing works

Increased Vulnerability to l-DOPA Toxicity in Dopaminergic Neurons From VMAT2 Heterozygote Knockout Mice

Kariya, S., Takahashi, N., Hirano, M., & Ueno, S. (2005) · Journal of Molecular Neuroscience · doi:10.1385/jmn:27:3:277 · Cited by 25 · see citing works

Vesicular Neurotransmitter Transporters*: Pharmacology, Biochemistry, and Molecular Analysis

Yelin, R., & Schuldiner, S. (2003) · Humana Press eBooks · doi:10.1385/1-59259-158-2:313 · Cited by 21 · see citing works

Syntheseversuche in der Emetin‐Reihe. 3. Mitteilung. 2‐Hydroxy‐hydrobenzo[a]chinolizine

BROSSI, A., Chopard‐dit‐Jean, L. H., & Schnider, O. (1958) · Helvetica Chimica Acta · doi:10.1002/hlca.19580410634 · Cited by 20 · see citing works

Binding of 125I‐iodovinyltetrabenazine to CNS vesicular monoamine transport sites

Kung, M., Canney, D. J., Frederick, D., Zhuang, Z., Billings, J. J., & Kung, H. F. (1994) · Synapse · doi:10.1002/syn.890180308 · Cited by 18 · see citing works

Characterization of a Series of 3-Amino-2-phenylpropene Derivatives as Novel Bovine Chromaffin Vesicular Monoamine Transporter Inhibitors

Perera, R. P., Wimalasena, D. S., & Wimalasena, K. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm030004p · Cited by 17 · see citing works

Synthesis and evaluation of a series of tropane analogues as novel vesicular monoamine transporter-2 ligands

Zheng, G., Dwoskin, L. P., Deaciuc, A. G., & Crooks, P. A. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2005.07.032 · Cited by 16 · see citing works

1-methyl-4-phenylpyridinium is a substrate of the vesicular monoamine uptake system of chromaffin granules

Scherman, D., Darchen, F., Desnos, C., & Henry, J. (1988) · European Journal of Pharmacology · doi:10.1016/0014-2999(88)90317-2 · Cited by 15 · see citing works

Pharmacological Investigation of (+)- and (−)-cis-2,3,3a,4,5,9b-Hexahydro-1-methyl-1 H-pyrrolo[3,2-h]isoquinoline, a Bridged-Nicotine Analog

Damaj, M. I., Glassco, W., Marks, M. J., Slobe, B. S., James, J. R., May, E. L., Rosecrans, J. A., Collins, A. C., & Martin, B. R. (1997) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36922-8 · Cited by 14 · see citing works

Synthesis and preliminary evaluation of an iodovinyl‐tetrabenazine analog as a marker for the vesicular monoamine transporter

Canney, D. J., Guo, Y., Kung, M., & Kung, H. F. (1993) · Journal of Labelled Compounds and Radiopharmaceuticals · doi:10.1002/jlcr.2580330413 · Cited by 13 · see citing works

Amino- and amido-tetrabenazine derivatives: Synthesis and evaluation as potential ligands for the vesicular monoamine transporter

Canney, D. J., Kung, M., & Kung, H. F. (1995) · Nuclear Medicine and Biology · doi:10.1016/0969-8051(94)00118-4 · Cited by 13 · see citing works

A benzo[a]quinolizine derivative with a neuroleptic-like action on cerebral monoamine turnover.

Saner, A., & Pletscher, A. (1977) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)31082-7 · Cited by 12 · see citing works

A series of hexahydro[1,4]oxazino[3,4-a]isoquinolines as potential neuroleptics

Clarke, F. H., Hill, R. T., Koo, J., Lopano, R. M., Maseda, M. A., Smith, M. E., Soled, S., Veh, G. V., & Vlattas, I. (1978) · Journal of Medicinal Chemistry · doi:10.1021/jm00206a013 · Cited by 11 · see citing works

Mutant mouse strains as models for in vivo radiotracer evaluations: [11C]methoxytetrabenazine ([11C]MTBZ) in Tottering mice

Kilbourn, M. R., Sherman, P. S., & Abbott, L. C. (1995) · Nuclear Medicine and Biology · doi:10.1016/0969-8051(95)00005-i · Cited by 10 · see citing works

Nicotine antagonists: phosphoinositide turnover and receptor binding to determine muscarinic properties

Banerjee, S., & Abood, L. G. (1989) · Biochemical Pharmacology · doi:10.1016/0006-2952(89)90454-1 · Cited by 9 · see citing works

2-Thio-1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-2H-benzo[a]quinolizines

Harnden, M. R., & Short, J. H. (1967) · Journal of Medicinal Chemistry · doi:10.1021/jm00318a051 · Cited by 7 · see citing works

A Role for the Vesicular Monoamine Transporter (VMAT2) in Parkinson’s Disease

German, D. C., & Sonsalla, P. K. (2002) · Advances in behavioral biology · doi:10.1007/978-1-4615-0179-4_13 · Cited by 6 · see citing works

Ketanserin as a Ligand of the Vesicular Monoamine Transporter

Henry, J., Gasnier, B., Isambert, M. F., Darchen, F., & Scherman, D. (1991) · Elsevier eBooks · doi:10.1016/b978-0-08-041165-1.50055-7 · Cited by 5 · see citing works

Synthesis and biological activity of iodinated and photosensitive derivatives of tetrabenazine

Aranda, G., Beaucourt, J. P., Ponchant, M., Isambert, M. F., & Henry, J. (1990) · European Journal of Medicinal Chemistry · doi:10.1016/0223-5234(90)90121-i · Cited by 5 · see citing works

Octahydrophenanthrene Analogs of Tetrabenazine

Fahrenholtz, K. E., Capomaggi, A. S., Lurie, M., Goldberg, M. W., & Kierstead, R. W. (1966) · Journal of Medicinal Chemistry · doi:10.1021/jm00321a009 · Cited by 3 · see citing works

Natural products: An evolving role in future drug discovery

Mishra, B. B., & Tiwari, V. K. (2011) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2011.07.057 · Cited by 866 · see citing works

Functional neuroanatomy of the noradrenergic locus coeruleus: its roles in the regulation of arousal and autonomic function part II: physiological and pharmacological manipulations and pathological alterations of locus coeruleus activity in humans

Samuels, E., & Szabadi, E. (2008) · Current Neuropharmacology · doi:10.2174/157015908785777193 · Cited by 454 · see citing works

Reward circuitry dysfunction in psychiatric and neurodevelopmental disorders and genetic syndromes: animal models and clinical findings

Dichter, G. S., Damiano, C. A., & Allen, J. A. (2012) · Journal of Neurodevelopmental Disorders · doi:10.1186/1866-1955-4-19 · Cited by 299 · see citing works

Parkinson’s Disease: Pathogenesis and Clinical Aspects

(2018) · Codon Publications eBooks · doi:10.15586/codonpublications.parkinsonsdisease.2018 · Cited by 295 · see citing works

Vesicular monoamine transporters: Structure‐function, pharmacology, and medicinal chemistry

Wimalasena, K. (2010) · Medicinal Research Reviews · doi:10.1002/med.20187 · Cited by 199 · see citing works

Functional Organization of the Sympathetic Pathways Controlling the Pupil: Light-Inhibited and Light-Stimulated Pathways

Szabadi, E. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.01069 · Cited by 145 · see citing works

Current and Possible Future Therapeutic Options for Huntington’s Disease

Ferguson, M. W., Kennedy, C. J., Palpagama, T. H., Waldvogel, H. J., Faull, R. L. M., & Kwakowsky, A. (2022) · Journal of Central Nervous System Disease · doi:10.1177/11795735221092517 · Cited by 126 · see citing works

Brain dopamine and serotonin differ in regulation and its consequences

Hashemi, P., Dankoski, E. C., Lama, R., Wood, K. M., Takmakov, P. A., & Wightman, R. M. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1201547109 · Cited by 111 · see citing works

Psychostimulant-induced alterations in vesicular monoamine transporter-2 function: Neurotoxic and therapeutic implications

Fleckenstein, A. E., Volz, T. J., & Hanson, G. R. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.07.002 · Cited by 100 · see citing works

Tourette??s Syndrome and Role??of??Tetrabenazine

Porta, M., Sassi, M., Cavallazzi, M., Fornari, M., Brambilla, A., & Servello, D. (2008) · Clinical Drug Investigation · doi:10.2165/00044011-200828070-00006 · Cited by 93 · see citing works

Vesicular monoamine transporter 2 regulates the sensitivity of rat dopaminergic neurons to disturbed cytosolic dopamine levels

Vergo, S. B., Johansen, J. L., Leist, M., & Lotharius, J. (2007) · Brain Research · doi:10.1016/j.brainres.2007.09.028 · Cited by 89 · see citing works

Altered expression of key dopaminergic regulatory proteins in the postnatal brain following perinatal n‐3 fatty acid dietary deficiency

Kuperstein, F., Eilam, R., & Yavin, E. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05418.x · Cited by 81 · see citing works

Tetrabenazine: Spotlight on Drug Review

Kaur, N., Kumar, P., Jamwal, S., Deshmukh, R. R., & Gauttam, V. K. (2016) · Annals of Neurosciences · doi:10.1159/000449184 · Cited by 79 · see citing works

Effect of high-fat feeding on expression of genes controlling availability of dopamine in mouse hypothalamus

Lee, A. K., Mojtahed-Jaberi, M., Kyriakou, T., Aldecoa-Otalora, E., Arno, M. J., Marshall, N. J., Brain, S. D., & O’Dell, S. D. (2009) · Nutrition · doi:10.1016/j.nut.2009.05.007 · Cited by 78 · see citing works

Monoamine oxidases in development

Wang, C. C., Billett, E. E., Borchert, A., Kühn, H., & Ufer, C. (2012) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-012-1065-7 · Cited by 77 · see citing works

The vesicular monoamine transporter 2: An underexplored pharmacological target

Bernstein, A. I., Stout, K. A., & Miller, G. W. (2014) · Neurochemistry International · doi:10.1016/j.neuint.2013.12.003 · Cited by 74 · see citing works

New Fluorescent Substrate Enables Quantitative and High-Throughput Examination of Vesicular Monoamine Transporter 2 (VMAT2)

Hu, G., Henke, A., Karpowicz, R. J., Sonders, M. S., Farrimond, F., Edwards, R. H., Sulzer, D. L., & Sameš, D. (2013) · ACS Chemical Biology · doi:10.1021/cb400259n · Cited by 69 · see citing works

Selection of sucrose concentration depends on the effort required to obtain it: studies using tetrabenazine, D1, D2, and D3 receptor antagonists

Pardo, M., López‐Cruz, L., Miguel, N. S., Salamone, J. D., & Correa, M. (2015) · Psychopharmacology · doi:10.1007/s00213-015-3872-7 · Cited by 66 · see citing works

Transport and inhibition mechanisms of human VMAT2

Wu, D., Chen, Q., Yu, Z., Huang, B., Zhao, J., Wang, Y., Su, J., Zhou, F., Yan, R., Li, N., et al. (2023) · Nature · doi:10.1038/s41586-023-06926-4 · Cited by 62 · see citing works

Neuroprotective effects of PACAP27 in mice model of Parkinson’s disease involved in the modulation of KATP subunits and D2 receptors in the striatum

Wang, G., Pan, J., Tan, Y., Sun, X., Zhang, Y., Zhou, H., Ren, R., Wang, X., & Chen, S. (2008) · Neuropeptides · doi:10.1016/j.npep.2008.03.002 · Cited by 57 · see citing works

Clinical Pharmacology of Dopamine-Modulating Agents in Tourette’s Syndrome

Mogwitz, S., Buse, J., Ehrlich, S., & Roessner, V. (2013) · International review of neurobiology · doi:10.1016/b978-0-12-411546-0.00010-x · Cited by 56 · see citing works

Antiepileptic activity of lobeline isolated from the leaf of Lobelia nicotianaefolia and its effect on brain GABA level in mice

Tamboli, A. M., Rub, R. A., Ghosh, P., & Bodhankar, S. (2012) · Asian Pacific Journal of Tropical Biomedicine · doi:10.1016/s2221-1691(12)60092-6 · Cited by 55 · see citing works

Tetrabenazine

Hayden, M. R., Leavitt, B. R., Yasothan, U., & Kirkpatrick, P. J. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2784 · Cited by 53 · see citing works

Using the affective bias test to predict drug‐induced negative affect: implications for drug safety

Stuart, S. A., Wood, C. M., & Robinson, E. S. J. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13972 · Cited by 52 · see citing works

Dopamine, vesicular transporters and dopamine receptor expression and localization in rat thymus and spleen

Mignini, F., Tomassoni, D., Traini, E., & Amenta, F. (2008) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2008.09.018 · Cited by 46 · see citing works

Melatonin mediated antidepressant-like effect in the hippocampus of chronic stress-induced depression rats: Regulating vesicular monoamine transporter 2 and monoamine oxidase A levels

Stefanović, B., Spasojević, N., Jovanović, P., Jasnic, N. I., Djordjevic, J. D., & Dronjak, S. (2016) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2016.07.005 · Cited by 46 · see citing works

In Vitro and In Vivo Characterization of the Alkaloid Nuciferine

Farrell, M. S., McCorvy, J. D., Huang, X., Urban, D. J., White, K. L., Giguère, P. M., Doak, A. K., Bernstein, A. I., Stout, K. A., Park, S. M., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0150602 · Cited by 45 · see citing works

Catecholamines up integrates dopamine synthesis and synaptic trafficking

Wang, Z., Ferdousy, F., Lawal, H. O., Huang, Z., Daigle, J. G., Izevbaye, I., Doherty, O. M., Thomas, J., Stathakis, D. G., & O’Donnell, J. M. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07517.x · Cited by 42 · see citing works

A Concise Total Synthesis of (+)‐Tetrabenazine and (+)‐α‐Dihydrotetrabenazine

Paek, S., Kim, N., Shin, D., Jung, J., Jung, J., Chang, D., Moon, H., & Suh, Y. (2010) · Chemistry - A European Journal · doi:10.1002/chem.200902591 · Cited by 41 · see citing works

Natural Products in Drug Discovery: Impacts and Opportunities — An Assessment

Brahmachari, G. (2011) · WORLD SCIENTIFIC eBooks · doi:10.1142/9789814335386_0001 · Cited by 42 · see citing works

Update on the Pharmacological Treatment of Tics with Dopamine-Modulating Agents

Mogwitz, S., Buse, J., Wolff, N., & Roessner, V. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.7b00460 · Cited by 37 · see citing works

Enzymatic Desymmetrization of Prochiral Molecules

Palomo, J. M., & Cabrera, Z. (2012) · Current Organic Synthesis · doi:10.2174/157017912803901628 · Cited by 35 · see citing works

Preparation and Characterization of Tetrabenazine Enantiomers against Vesicular Monoamine Transporter 2

Yu, Q., Luo, W., Deschamps, J. R., Holloway, H. W., Kopajtic, T. A., Katz, J. L., Brossi, A. R., & Greig, N. H. (2010) · ACS Medicinal Chemistry Letters · doi:10.1021/ml1000189 · Cited by 32 · see citing works

Classic animal models of Parkinson’s disease: a historical perspective

Hamadjida, A., Frouni, I., Kwan, C., & Huot, P. (2018) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000441 · Cited by 32 · see citing works

Tetrabenazine inhibition of monoamine uptake and methamphetamine behavioral effects: Locomotor activity, drug discrimination and self-administration

Meyer, A. C., Horton, D. B., Neugebauer‎, N. M., Wooters, T. E., Nickell, J. R., Dwoskin, L. P., & Bardo, M. T. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.05.033 · Cited by 31 · see citing works

The effect of a novel VMAT2 inhibitor, GZ-793A, on methamphetamine reward in rats

Beckmann, J. S., Denehy, E. D., Zheng, G., Crooks, P. A., Dwoskin, L. P., & Bardo, M. T. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2488-9 · Cited by 31 · see citing works

Synthesis of (±)-Tetrabenazine by Visible Light Photoredox Catalysis

Calabretta, L. O., Maverick, E. E., & Marvin, C. C. (2015) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.5b02199 · Cited by 30 · see citing works

A Ring-Closing Metathesis-Based Approach to the Synthesis of (+)-Tetrabenazine

Johannes, M., & Altmann, K. (2012) · Organic Letters · doi:10.1021/ol301612q · Cited by 30 · see citing works

Surveillance for an emerging disease: dengue hemorrhagic fever in Puerto Rico, 1988-1997. Puerto Rico Association of Epidemiologists.

Rigau-Pérez, J. G. (1999) · PubMed · Cited by 30 · see citing works

Synthesis and evaluation of a series of homologues of lobelane at the vesicular monoamine transporter-2

Zheng, G., Dwoskin, L. P., Deaciuc, A. G., & Crooks, P. A. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.10.042 · Cited by 29 · see citing works

Association between variation in the vesicular monoamine transporter 1 gene on chromosome 8p and anxiety-related personality traits

Lohoff, F. W., Lautenschlager, M. M., Mohr, J., Ferraro, T. N., Sander, T., & Gallinat, J. (2008) · Neuroscience Letters · doi:10.1016/j.neulet.2008.01.024 · Cited by 29 · see citing works

Drug-induced hyperkinetic movement disorders by nonneuroleptic agents

Zesiewicz, T. A., & Sullivan, K. L. (2011) · Handbook of clinical neurology · doi:10.1016/b978-0-444-52014-2.00027-6 · Cited by 28 · see citing works

Genetic Variants in the Vesicular Monoamine Transporter 1 (VMAT1/SLC18A1) and Neuropsychiatric Disorders

Lohoff, F. W. (2010) · Methods in molecular biology · doi:10.1007/978-1-60761-700-6_9 · Cited by 27 · see citing works

Effects of VMAT 2 inhibitors lobeline and GZ ‐793A on methamphetamine‐induced changes in dopamine release, metabolism and synthesis in vivo

Meyer, A. C., Neugebauer‎, N. M., Zheng, G., Crooks, P. A., Dwoskin, L. P., & Bardo, M. T. (2013) · Journal of Neurochemistry · doi:10.1111/jnc.12373 · Cited by 24 · see citing works

N-terminus regulation of VMAT2 mediates methamphetamine-stimulated efflux

Torres, B., & Ruoho, A. E. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.11.059 · Cited by 22 · see citing works

Dopamine D2 Receptor Relies upon PPM/PP2C Protein Phosphatases to Dephosphorylate Huntingtin Protein

Marion, S., Urs, N. M., Peterson, S. M., Sotnikova, T. D., Beaulieu, J., Gainetdinov, R. R., & Caron, M. G. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.544312 · Cited by 21 · see citing works

Pyrrolidine Analogues of Lobelane: Relationship of Affinity for the Dihydrotetrabenazine Binding Site with Function of the Vesicular Monoamine Transporter 2 (VMAT2)

Vartak, A. P., Nickell, J. R., Chagkutip, J., Dwoskin, L. P., & Crooks, P. A. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900770h · Cited by 20 · see citing works

Experimenting with Spirituality: AnalyzingThe God Genein a Nonmajors Laboratory Course

Silveira, L. A. (2008) · CBE—Life Sciences Education · doi:10.1187/cbe.07-05-0029 · Cited by 18 · see citing works

A Triple Play for Thyroid Hormone

Weatherman, R. V. (2007) · ACS Chemical Biology · doi:10.1021/cb700104v · Cited by 18 · see citing works

Beyond Alkaloids: Novel Bioactive Natural Products From Lobelia Species

Zheng, Q., Wang, Y., & Zhang, S. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.638210 · Cited by 17 · see citing works

Tetrabenazine for treatment of chorea associated with Huntington's disease and other potential indications

Shahed, J. J., & Jankovic, J. J. (2013) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2013.787358 · Cited by 17 · see citing works

Oral administration of GZ-793A, a VMAT2 inhibitor, decreases methamphetamine self-administration in rats

Wilmouth, C. E., Zheng, G., Crooks, P. A., Dwoskin, L. P., & Bardo, M. T. (2013) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2013.09.006 · Cited by 16 · see citing works

The effect of VMAT2 inhibitor GZ-793A on the reinstatement of methamphetamine-seeking in rats

Alvers, K. M., Beckmann, J. S., Zheng, G., Crooks, P. A., Dwoskin, L. P., & Bardo, M. T. (2012) · Psychopharmacology · doi:10.1007/s00213-012-2748-3 · Cited by 16 · see citing works

Novel hypoglycemic dihydropyridones serendipitously discovered from O- versus C-alkylation in the synthesis of VMAT2 antagonists

Xie, Y., Raffo, A. J., Ichise, M., Deng, S., Harris, P. E., & Landry, D. W. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.07.129 · Cited by 16 · see citing works

Meta-analysis and systematic review of vesicular monoamine transporter (VMAT-2) inhibitors in schizophrenia and psychosis

Connolly, A., Wallman, P., Dzahini, O., Howes, O. D., & Taylor, D. M. (2024) · Psychopharmacology · doi:10.1007/s00213-023-06488-3 · Cited by 15 · see citing works

Deletion of the vesicular monoamine transporter 1 (vmat1/slc18a1) gene affects dopamine signaling

Lohoff, F. W., Carr, G. V., Brookshire, B. R., Ferraro, T. N., & Lucki, I. (2019) · Brain Research · doi:10.1016/j.brainres.2019.01.029 · Cited by 15 · see citing works

Neurotransmitter recognition by human vesicular monoamine transporter 2

Im, D., Jormakka, M., Juge, N., Kishikawa, J.-I., Kato, T., Sugita, Y., Noda, T., Uemura, T., Shiimura, Y., Miyaji, T., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-51960-z · Cited by 14 · see citing works

Synthesis of (+)- and (−)-Tetrabenazine from the Resolution of α-Dihydrotetrabenazine

Boldt, K. G., Biggers, M. S., Phifer, S. S., Brine, G. A., & Rehder, K. S. (2009) · Synthetic Communications · doi:10.1080/00397910902788125 · Cited by 14 · see citing works

Sex differences in tolerance to the locomotor depressant effects of lobeline in periadolescent rats

Harrod, S. B., & Horn, M. L. V. (2009) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2009.09.009 · Cited by 14 · see citing works

18F-AV-133: A Selective VMAT2-binding Radiopharmaceutical for PET Imaging of Dopaminergic Neurons

Hefti, F. F., Kung, H. F., Kilbourn, M. R., Carpenter, A. P., Clark, C. M., & Skovronsky, D. (2010) · PET Clinics · doi:10.1016/j.cpet.2010.02.001 · Cited by 14 · see citing works

Stereoselective neuroimaging in vivo

Smith, D. F., & Jakobsen, S. (2007) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2007.02.008 · Cited by 13 · see citing works

VMAT2 Inhibitors for Tardive Dyskinesia—Practice Implications

Peckham, A. M., & Nicewonder, J. A. (2018) · Journal of Pharmacy Practice · doi:10.1177/0897190018756512 · Cited by 12 · see citing works

Synthesis of (−)-lobeline via enzymatic desymmetrization of lobelanidine

Chênevert, R., & Morin, P. (2009) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2009.01.055 · Cited by 12 · see citing works

Synthesis of Lobeline, Lobelane and their Analogues. A Review

Zheng, G., & Crooks, P. A. (2015) · Organic Preparations and Procedures International · doi:10.1080/00304948.2015.1066642 · Cited by 11 · see citing works

Lobeline esters as novel ligands for neuronal nicotinic acetylcholine receptors and neurotransmitter transporters

Hojahmat, M., Horton, D. B., Norrholm, S. D., Miller, D. K., Grinevich, V. P., Deaciuc, A. G., Dwoskin, L. P., & Crooks, P. A. (2009) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2009.12.002 · Cited by 11 · see citing works

A New VMAT ‐2 Inhibitor NBI ‐641449 in the Treatment of Huntington Disease

Chen, S., Zhang, X., Xie, W., Qiu, H., Liu, H., & Le, W. (2015) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12425 · Cited by 11 · see citing works

Synthesis and biological evaluation of 3-alkyl-dihydrotetrabenazine derivatives as vesicular monoamine transporter-2 (VMAT2) ligands

Zheng, P., Lieberman, B. P., Choi, S., Plöessl, K., & Kung, H. F. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.03.113 · Cited by 11 · see citing works

Tetrabenazine improves levodopa-induced peak-dose dyskinesias in patients with Parkinson�s disease

Brusa, L. (2013) · Functional Neurology · doi:10.11138/fneur/2013.28.2.101 · Cited by 10 · see citing works

T-2 toxin triggers depression-like behaviors via upregulation of dopamine transporter in nucleus accumbens of male mice

Chen, Z., Duan, S., Li, J., Su, J., & Lei, H. (2024) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2024.117392 · Cited by 9 · see citing works

Vesicular Neurotransmitter Transporters

Fei, H., & Krantz, D. E. (2009) · Springer eBooks · doi:10.1007/978-0-387-30370-3_7 · Cited by 9 · see citing works

The metabolism of histamine in rat hypothalamus and cortex after reserpine treatment

Maldonado, M., & Maeyama, K. (2015) · Neurochemistry International · doi:10.1016/j.neuint.2015.04.005 · Cited by 9 · see citing works

Altered expression of vesicular monoamine transporter 2 in epileptic patients and experimental rats

Jiang, G., Cao, Q., Li, J., Zhang, Y., Liu, X., Wang, Z., Guo, F., Chen, Y., Chen, Y., Chen, G., et al. (2013) · Synapse · doi:10.1002/syn.21663 · Cited by 9 · see citing works

Hippocampal asymmetry in expression of catecholamine synthesizing enzyme and transporters in socially isolated rats.

Spasojević, N., Stanisavljevic, D., Gavrilović, L., Jovanović, P., Cucakovic, A., & Dronjak, S. (2012) · PubMed · Cited by 9 · see citing works

Exploring the effect of N-substitution in nor-lobelane on the interaction with VMAT2: discovery of a potential clinical candidate for treatment of methamphetamine abuse

Zheng, G., Horton, D. B., Penthala, N. R., Nickell, J. R., Culver, J. P., Deaciuc, A. G., Dwoskin, L. P., & Crooks, P. A. (2013) · MedChemComm · doi:10.1039/c3md20374c · Cited by 9 · see citing works

SYNTHESIS OF (+)-9-O-DESMETHYL-α-DIHYDROTETRABENAZINE, PRECURSOR FOR THE HIGH AFFINITY VMAT2 IMAGING PET RADIOLIGAND [ 11 C]-(+)-α-DIHYDROTETRABENAZINE

Boldt, K. G., Brine, G. A., & Rehder, K. S. (2008) · Organic Preparations and Procedures International · doi:10.1080/00304940809458097 · Cited by 9 · see citing works

MicroPET/CT assessment of neurochemical effects in the brain after long-term methylphenidate treatment in nonhuman primates

Zhang, X., Talpos, J. C., Berridge, M. S., Apana, S. M., Slikker, W., Wang, C., & Paule, M. G. (2021) · Neurotoxicology and Teratology · doi:10.1016/j.ntt.2021.107017 · Cited by 8 · see citing works

Effect of Carbidopa on 18F-FDOPA Uptake in Insulinoma: From Cell Culture to Small-Animal PET Imaging

Détour, J., Pierre, A., Boisson, F., Kreutter, G., Lavaux, T., Namer, I. J., Kessler, L., Brasse, D., Marchand, P., & Impériale, A. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.180588 · Cited by 8 · see citing works

Neuronal Networks Regulating Sleep and Arousal: Effect of Drugs

Szabadi, E. (2014) · Milestones in drug therapy · doi:10.1007/978-3-319-11514-6_2 · Cited by 8 · see citing works

Structural insights into substrate transport and drug inhibition of the human vesicular monoamine transporter 2 ( VMAT2 )

Wu, D., Zhao, Y., & Jiang, D. (2025) · FEBS Journal · doi:10.1111/febs.70003 · Cited by 8 · see citing works

Grignard Reagents as Niche Bases in the Synthesis of Pharmaceutically Relevant Molecules

Samineni, R., Eda, V. V. R., Rao, P., Sen, S., & Oruganti, S. (2022) · ChemistrySelect · doi:10.1002/slct.202102853 · Cited by 7 · see citing works

Stereocontrolled Synthesis and Pharmacological Evaluation ofcis-2,6-Diphenethyl-1-azabicyclo[2.2.2]octanes as Lobelane Analogues

Zheng, G., Dwoskin, L. P., Deaciuc, A. G., & Crooks, P. A. (2009) · The Journal of Organic Chemistry · doi:10.1021/jo901082r · Cited by 7 · see citing works

Vesicular monoamine transporter-2 inhibitor JPC-141 prevents methamphetamine-induced dopamine toxicity and blocks methamphetamine self-administration in rats

Chandler, C. M., Nickell, J. R., Wilson, A. G., Culver, J. P., Crooks, P. A., Bardo, M. T., & Dwoskin, L. P. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116189 · Cited by 6 · see citing works

Evidence for low affinity of GABA at the vesicular monoamine transporter VMAT2 – Implications for transmitter co-release from dopamine neurons

Srinivasan, S., Limani, F., Hanzlova, M., Batide-Alanore, S. L., Klotz, S., Hnasko, T. S., & Steinkellner, T. (2025) · Neuropharmacology · doi:10.1016/j.neuropharm.2025.110367 · Cited by 8 · see citing works

Chemical probes based on GOLD : The discovery and elucidation of mechanism

Ciaramicoli, L. M., & Chang, Y. (2023) · Bulletin of the Korean Chemical Society · doi:10.1002/bkcs.12713 · Cited by 5 · see citing works

Fluoroethoxy-1,4-diphenethylpiperidine and piperazine derivatives: Potent and selective inhibitors of [3H]dopamine uptake at the vesicular monoamine transporter-2

Hankosky, E. R., Joolakanti, S. R., Nickell, J. R., Janganati, V., Dwoskin, L. P., & Crooks, P. A. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.10.039 · Cited by 5 · see citing works

Synthesis of 3H‐labeled Tetrabenazine (TBZ)

Rhee, S., Ryan, K. J., & Tanga, M. J. (2011) · Journal of Labelled Compounds and Radiopharmaceuticals · doi:10.1002/jlcr.1881 · Cited by 5 · see citing works

Simple, Rapid and Reliable Preparation of [11C]-(+)-a-DTBZ of High Quality for Routine Applications

Zhang, J., Zhang, X., Li, Y., & Tian, J. (2012) · Molecules · doi:10.3390/molecules17066697 · Cited by 5 · see citing works

Synthesis and preliminary evaluation of 131I-9-iodovinyl-tetrabenazine targeting vesicular monoamine transporter 2

Cao, L., Xie, M., Zhao, C., Tang, J., Liu, C., Xu, Y., Li, X., Liu, Y., & Chen, Z. (2018) · Journal of Radioanalytical and Nuclear Chemistry · doi:10.1007/s10967-018-5900-7 · Cited by 4 · see citing works

Protective effects of amphetamine and methylphenidate against dopaminergic neurotoxicants in SH-SY5Y cells

Carneiro, P., Ferreira, M., Costa, V. M., Carvalho, F. D., & Capela, J. P. (2024) · Current Research in Toxicology · doi:10.1016/j.crtox.2024.100165 · Cited by 4 · see citing works

P25α / TPPP expression increases plasma membrane presentation of the dopamine transporter and enhances cellular sensitivity to dopamine toxicity

Fjorback, A. W., Sundbye, S., Dächsel, J. C., Sinning, S., Wiborg, O., & Jensen, P. H. (2010) · FEBS Journal · doi:10.1111/j.1742-4658.2010.07970.x · Cited by 4 · see citing works

Alkaloids

Wiart, C. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-398373-2.00001-7 · Cited by 4 · see citing works

In Silico ADME, Molecular Targets, Docking and Molecular Dynamics Simulation of Key Phytoconstituents of Lobelia inflata

Ajayi, I. I., Fatoki, T. H., Alonge, S. A., Balogun, T. C., Nwagwe, O. R., Moge, G. M., & Shityakov, S. (2024) · Journal of Computational Biophysics and Chemistry · doi:10.1142/s2737416524500480 · Cited by 3 · see citing works

SPECT/PET Findings in Lewy Body Dementia

Ducksbury, R., Whitfield, T. J., & Walker, Z. (2014) · Springer eBooks · doi:10.1007/978-3-642-54307-4_17 · Cited by 3 · see citing works

Structural requirement of C11b chirality of tetrabenazine analogs as VMAT2 imaging ligands: synthesis and in vivo evaluation

Xue, D., Liu, C., Li, X., Tang, J., Cao, L., Liu, Y., & Chen, Z. (2017) · Journal of Radioanalytical and Nuclear Chemistry · doi:10.1007/s10967-017-5333-8 · Cited by 3 · see citing works

SPECT/PET Findings in Dementia with Lewy Bodies

Zabihi, S., Whitfield, T. J., & Walker, Z. (2020) · Springer eBooks · doi:10.1007/978-3-030-53168-3_17 · Cited by 3 · see citing works

Evidence for low affinity of GABA at the vesicular monoamine transporter VMAT2 – implications for transmitter co-release from dopamine neuronsPreprint

Limani, F., Srinivasan, S., Hanzlova, M., Batide-Alanore, S. L., Klotz, S., Hnaskoxs, T. S., & Steinkellner, T. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.07.04.602053 · Cited by 3 · see citing works

Effects of methamphetamine isomers on d-methamphetamine self-administration and food-maintained responding in male rats

Bardo, M. T., Denehy, E. D., Hammerslag, L. R., Dwoskin, L. P., Blough, B. E., Landavazo, A., Bergman, J., & Kohut, S. J. (2019) · Psychopharmacology · doi:10.1007/s00213-019-05327-8 · Cited by 2 · see citing works

In vivo and in vitro binding of [125I]I‐R‐(+)‐TISCH: A dopamine D1 receptor ligand for studying pancreatic β‐cell mass

Zhang, Y., Li, G., Sun, Y., Hong, H., Li, L., Luo, Y., Wang, R., Zhu, L., Kung, H. F., & Zhu, J. (2022) · Journal of Labelled Compounds and Radiopharmaceuticals · doi:10.1002/jlcr.4005 · Cited by 2 · see citing works

Pharmacological Properties of Levodopa

Huot, P. (2014) · Springer eBooks · doi:10.1007/978-1-4471-6503-3_9 · Cited by 2 · see citing works

Therapy for dyskinesias in Parkinson‘s disease patients

Stefani, A., Pierantozzi, M., Koch, G., Galati, S., & Stanzione, P. (2009) · Future Neurology · doi:10.2217/fnl.10.9 · Cited by 2 · see citing works

Monoamine Transporter Inhibitors

Perera, R. P. (2010)

Psychostimulant-induced alterations in vesicular monoamine transporter-2 function: Neurotoxic and therapeutic implications

Fleckenstein, A. E., Volz, T. J., & Hanson, G. R. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.07.002 · Cited by 100 · see citing works

Synthesis and analysis of dihydrotetrabenazine derivatives as novel vesicular monoamine transporter 2 inhibitors

Yang, Y. K., Yu, D., Zhu, X., Du, G., Wang, W., Zou, F., Wang, H., Zhang, R., Ye, L., & Tian, J. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113718 · Cited by 9 · see citing works

Vesicular Monoamine Transporters at the Crossroads of Structure and Function: Advances, Challenges, and Future Perspectives

Lange, K. H., Dalton, M. P., Mandal, S. K., & Coleman, J. A. (2026) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-060225-123449

Structural mechanisms for VMAT2 inhibition by tetrabenazine

Dalton, M. P., Cheng, M. H., Bahar, İ., & Coleman, J. A. (2024) · Biophysical Journal · doi:10.1016/j.bpj.2023.11.815